113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
SGLT2 抑制剂在肿瘤联合治疗中的应用：协同治疗策略的新途径
Authors Su H, Li X, Wang S, Yang X, Jiang L , Luo H, Li Y, Zhou J, Huang Y, Li M
Received 25 July 2025
Accepted for publication 10 December 2025
Published 26 December 2025 Volume 2025:19 Pages 11817—11847
DOI https://doi.org/10.2147/DDDT.S556231
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Mariana Carmen Chifiriuc
Hao Su,1,2,* Xiangyu Li,1,2,* Shurong Wang,1,2,* Xuping Yang,1,2 Longyang Jiang,1,2 Hengli Luo,1,2 Yaping Li,1,2 Jie Zhou,1,2 Yilan Huang,1,2 Min Li1,2
1Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People’s Republic of China; 2School of Pharmacy, Southwest Medical University, Luzhou, 646000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yilan Huang, Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China, Email hyl3160131@126.com Min Li, Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China, Email limin0321@swmu.edu.cn
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed for glycemic control in type 2 diabetes, have shown potential therapeutic effects in cancer treatment. Studies suggest that SGLT2 inhibitors can suppress tumor growth and proliferation through the modulation of metabolic reprogramming in tumor cells, inhibition of tumor glucose uptake, and regulation of the tumor microenvironment. Recent studies have emphasized the potential benefits of combining SGLT2 inhibitors with conventional anticancer therapies, including chemotherapy (CT), immunotherapy, and targeted therapies. Several clinical trials are currently evaluating the safety and efficacy of these combinations. Both preclinical and clinical studies primarily explore the effectiveness of SGLT2 inhibitors in inhibiting tumor growth, reducing metastasis, and enhancing treatment outcomes. Identifying combination therapies with SGLT2 inhibitors could enable more personalized treatment selection and optimization. This review provides a comprehensive summary of the antitumor effects and underlying mechanisms of SGLT2 inhibitors when combined with conventional anticancer therapies, aiming to elucidate their emerging role in cancer treatment. Combination regimens involving SGLT2 inhibitors have the prospect to overcome certain limitations of monotherapy, offering promising clinical benefits and improving patient outcomes.
Keywords: SGLT2 inhibitors, tumor metabolism, antineoplastic agents, anticancer therapy, combination therapy
1Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People’s Republic of China; 2School of Pharmacy, Southwest Medical University, Luzhou, 646000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yilan Huang, Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China, Email hyl3160131@126.com Min Li, Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China, Email limin0321@swmu.edu.cn
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed for glycemic control in type 2 diabetes, have shown potential therapeutic effects in cancer treatment. Studies suggest that SGLT2 inhibitors can suppress tumor growth and proliferation through the modulation of metabolic reprogramming in tumor cells, inhibition of tumor glucose uptake, and regulation of the tumor microenvironment. Recent studies have emphasized the potential benefits of combining SGLT2 inhibitors with conventional anticancer therapies, including chemotherapy (CT), immunotherapy, and targeted therapies. Several clinical trials are currently evaluating the safety and efficacy of these combinations. Both preclinical and clinical studies primarily explore the effectiveness of SGLT2 inhibitors in inhibiting tumor growth, reducing metastasis, and enhancing treatment outcomes. Identifying combination therapies with SGLT2 inhibitors could enable more personalized treatment selection and optimization. This review provides a comprehensive summary of the antitumor effects and underlying mechanisms of SGLT2 inhibitors when combined with conventional anticancer therapies, aiming to elucidate their emerging role in cancer treatment. Combination regimens involving SGLT2 inhibitors have the prospect to overcome certain limitations of monotherapy, offering promising clinical benefits and improving patient outcomes.
Keywords: SGLT2 inhibitors, tumor metabolism, antineoplastic agents, anticancer therapy, combination therapy